We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+29.52%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.72B
AUM Growth
+$775M
Cap. Flow
-$10.2M
Cap. Flow %
-0.22%
Top 10 Hldgs %
24.37%
Holding
169
New
21
Increased
56
Reduced
46
Closed
14

Top Buys

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$54.7M
2
EAR
Eargo, Inc. Common Stock
EAR
+$37.9M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$37.2M
4
SPRB
Spruce Biosciences
SPRB
+$36M
5
LUNG icon
Pulmonx
LUNG
+$24.5M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$135M
2
CNC icon
Centene
CNC
+$37.5M
3
BAX icon
Baxter International
BAX
+$27.2M
4
ASMB icon
Assembly Biosciences
ASMB
+$24.1M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$21M

Sector Composition

Rank Sector Weight
1 Healthcare 92.97%
2 Consumer Staples 1.52%
3 Consumer Discretionary 0.76%
4 Industrials 0.46%
5 Financials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
51
CALL
Biogen
BIIB
$30.6B
$31.8M 0.67%
+130,000
New +$33.5M
NVCR icon
52
NovoCure
NVCR
$2.02B
$30.3M 0.64%
175,000
– –
LONA
53
LeonaBio Inc
LONA
$70.5M
$29.5M 0.63%
86,090
-24,180
-22% -$5.7M
BSX icon
54
Boston Scientific
BSX
$73.1B
$28.8M 0.61%
800,000
-300,000
-27% -$10.8M
BFAM icon
55
Bright Horizons
BFAM
$3.81B
$28.6M 0.61%
165,500
– –
MDGL icon
56
Madrigal Pharmaceuticals
MDGL
$11.9B
$28.5M 0.61%
256,768
+2,500
+1% +$306K
TVTX icon
57
Travere Therapeutics
TVTX
$5.74B
$27.8M 0.59%
1,021,000
-3,261
-0.3% -$76.1K
PEN icon
58
Penumbra
PEN
$12.8B
$27.8M 0.59%
159,000
– –
EPZM
59
DELISTED
Epizyme, Inc
EPZM
$27.7M 0.59%
2,553,208
+1,549
+0.1% +$19.1K
MIRM icon
60
Mirum Pharmaceuticals
MIRM
$6.02B
$26.1M 0.55%
1,496,525
+168,911
+13% +$3.32M
INCY icon
61
Incyte
INCY
$24.6B
$26.1M 0.55%
300,000
– –
PRLD icon
62
Prelude Therapeutics
PRLD
$385M
$25.8M 0.55%
360,363
+100
+0% +$4.97K
GH icon
63
Guardant Health
GH
$22.4B
$25.8M 0.55%
200,000
+10,000
+5% +$1.15M
STTK icon
64
Shattuck Labs
STTK
$682M
$25.6M 0.54%
+489,000
New +$15.7M
TGTX icon
65
TG Therapeutics
TGTX
$7.52B
$25.4M 0.54%
489,000
-193,926
-28% -$6.55M
KRTX
66
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$24.8M 0.53%
243,950
-156
-0.1% -$14.5K
BIIB icon
67
Biogen
BIIB
$30.6B
$24.5M 0.52%
100,000
-72,500
-42% -$18.7M
BAX icon
68
Baxter International
BAX
$14.4B
$24.2M 0.51%
301,000
-344,000
-53% -$27.2M
RPRX icon
69
Royalty Pharma
RPRX
$25.8B
$24M 0.51%
480,000
-5,000
-1% -$212K
SPRO icon
70
Spero Therapeutics
SPRO
$71.2M
$23.9M 0.51%
1,235,000
-1,256
-0.1% -$19.6K
FOLD
71
DELISTED
Amicus Therapeutics
FOLD
$23.8M 0.5%
1,029,000
+5,179
+0.5% +$106K
OSH
72
DELISTED
Oak Street Health, Inc.
OSH
$22.9M 0.49%
375,000
+75,000
+25% +$3.93M
SWAV
73
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$22.8M 0.48%
220,000
– –
BMRN icon
74
BioMarin Pharmaceuticals
BMRN
$13.3B
$22.2M 0.47%
253,500
-96,500
-28% -$7.65M
COLL icon
75
Collegium Pharmaceutical
COLL
$882M
$22M 0.47%
1,100,000
-75,000
-6% -$1.46M
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Rock Springs Capital Management held 169 positions worth $4.72B, up 20% from $3.94B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rock Springs Capital Management's Q4 2020 filing shows 21 new, 56 increased, 46 reduced and 14 closed positions. Its largest new stake was Atea Pharmaceuticals: 1,697,403 shares worth $70.9M. The largest sale was Immunomedics Inc, an estimated $135M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 90% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q4 2020 buy was Atea Pharmaceuticals: 1,697,403 shares worth $70.9M.
  • Rock Springs Capital Management added most to Agios Pharmaceuticals in Q4 2020, an estimated $37.2M increase.
  • Rock Springs Capital Management's biggest Q4 2020 reduction was Centene, cutting an estimated $37.5M.
  • Rock Springs Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $135M.
  • Rock Springs Capital Management's ten largest holdings make up 24% of its $4.72B portfolio in Q4 2020.
  • Rock Springs Capital Management opened 21 new positions and closed 14 in Q4 2020.
  • Rock Springs Capital Management's portfolio value rose 20% quarter-over-quarter to $4.72B.

Based on Rock Springs Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.